OneAscent Financial Services LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

OneAscent Financial Services LLC grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 179.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,798 shares of the company's stock after purchasing an additional 3,082 shares during the period. OneAscent Financial Services LLC's holdings in Eli Lilly and Company were worth $3,704,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Private Portfolio Partners LLC boosted its stake in shares of Eli Lilly and Company by 16.8% during the 4th quarter. Private Portfolio Partners LLC now owns 3,189 shares of the company's stock worth $2,462,000 after purchasing an additional 459 shares during the period. Kesler Norman & Wride LLC lifted its stake in Eli Lilly and Company by 18.9% in the fourth quarter. Kesler Norman & Wride LLC now owns 4,774 shares of the company's stock worth $3,685,000 after purchasing an additional 760 shares during the last quarter. RFG Bristol Wealth Advisors LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth about $2,071,000. Meeder Advisory Services Inc. boosted its position in shares of Eli Lilly and Company by 3.4% during the fourth quarter. Meeder Advisory Services Inc. now owns 16,302 shares of the company's stock valued at $12,585,000 after buying an additional 541 shares during the period. Finally, Groupama Asset Managment grew its stake in shares of Eli Lilly and Company by 3.8% during the fourth quarter. Groupama Asset Managment now owns 91,838 shares of the company's stock valued at $71,068,000 after buying an additional 3,373 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $14.34 during midday trading on Wednesday, hitting $819.57. The company had a trading volume of 2,678,114 shares, compared to its average volume of 3,311,810. The stock has a market cap of $777.09 billion, a price-to-earnings ratio of 69.99, a PEG ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a fifty day simple moving average of $848.85 and a 200 day simple moving average of $834.05.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has authorized a stock buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's management believes its shares are undervalued.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a research note on Thursday, March 6th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Finally, Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.